For the clinical phase, Bayer has acquired the sole global license for an MTA-cooperative PRMT5 inhibitor that targets MTAP-deleted tumors selectively.
Eliminating amyloid from the brain may prevent symptoms in those who are destined to acquire early-onset Alzheimer’s disease, according to a clinical experiment. This suggests the need for additional research.
New active components, such as antibodies, are often evaluated separately in laboratory animals. Researchers at UZH have now created a method that can test up to 25 antibodies in a single mouse. This could not only accelerate the research and development pipeline for new pharmaceuticals, but also significantly reduce the number of experimental animals needed.
The researchers created a highly effective conversion technique using mouse cells that can generate over ten neurons from a single skin cell.
Bioreactors are specialized containers that allow the controlled development of cells, enzymes, or microbes. Environmental engineering, biotechnology, and pharmaceuticals are just a few of the disciplines in which they are essential. What is a Bioreactor? A bioreactor is an equipment or container that offers a regulated setting for biological processes […]
The researchers found that the tumor was produced by more than only the T cells’ present genetic changes.
The first medication approved by the FDA to treat CTX, a rare lipid storage condition, is Ctexli.
Utilizing reduced Takumi-shaped DNA nanostructures, researchers create optimal DNA hydrogels with possible biological uses.
Rare yet debilitating disorders, Dravet syndrome, and other developing epileptic encephalopathies induce a variety of symptoms in children, such as seizures, intellectual incapacity, and even unexpected death. The majority of cases are brought on by a genetic mutation; variations in the sodium channel gene SCN1A are most frequently the cause […]
The U.S. Food and Drug Administration (FDA) has approved GOMEKLI™ (mirdametinib), SpringWorks Therapeutics, Inc.’s MEK inhibitor, for the treatment of adult and pediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection. SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company […]
